Thalassemia and other hemoglobin abnormalities are the most common hereditary diseases in Thailand as well as other parts of the world. Around 5.2 percent of the world population are carriers of thalassemia and other hemoglobin abnormalities. People in such number have a 1.1 percent risk of having a child with thalassemia and other hemoglobin abnormalities, which is equal
s to 2.7 out of 2,000 people. For that reason, severe thalassemia prevention and control in newborn patients are greatly important.
During 2017-2021, Thalassemia Research Center provided genetics consultation services to 129 pregnant women and husbands who had risks of having their children with thalassemia at Thalassemia Clinic, Nakhon Pathom Hospital. Suggestions and practices of amniocentesis were provided to 49 pregnant women who may have their children with three severe thalassemias, which the Ministry of Public Health had their policy on prevention and control, which helps reduce the costs of thalassemia treatment for the patients’ families and the ministry.
The purposes of such amniocentesis are to develop disease and carrier diagnostics with precise and concise cellular, protein and molecular genetic methods, and to apply that as thalassemia diagnostic and treatment guidelines, as well as guidelines for thalassemia patients care in general practices.